MicroPort La Fenice® GnRH Infusion Pump Brought Light to Sterility Patients

MicroPort La Fenice® GnRH Infusion Pump, the first pulsatile GnRH infusion pump in China, has brought light to sterility patients.
In recent years, the rate of infertility has risen to 12.5% in China, among which are suffered from Idiopathic Hypogonadotropic Hypogonadism (IHH). IHH, also known as Kallmann Syndrome, is a genetic disorder marked by anosmia and hypogonadism. Abnormalities in various genes may cause a defect in the hypothalamus, causing a deficiency of gonadotropin-releasing hormone (GnRH). This in turn causes deficiency in Follicle-Stimulating Hormone (FSH) and luteinizing hormone (LH) levels. Incidence rate of IHH is 0.0005% in male, and 0.00001% in female. Even though R&D efforts related to the treatment have been going on for years in China, the ideal treatment for it had yet been available until the advent of MicroPort La Fenice® GnRH Infusion Pump.
This product stimulates hypophysis to excrete FSH/ LH by simulating pulse excretion of human gonadotropin-releasing hormone (GnRH) in order to make patients recover from abnormally physiological regulated function. Via treatment, patients can increase and maintain secondary sex characters, improve the deficiency of grown-up growth hormone (GH) and bone mineral density (BMD), regain fertility, and reduce the risk of cardiovascular events.
Up until now, there have been two male IHH patients impregnated their partners and other two female patients have been fertilized successfully.